ACELRX PHARMACEUTICALS INC - FORM S-1/A - EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - January 7, 2011

Attached files

file filename
S-1/A - AMENDMENT NO. 2 TO FORM S-1 - ACELRX PHARMACEUTICALS INCds1a.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - ACELRX PHARMACEUTICALS INCdex11.htm
EX-3.2 - FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - ACELRX PHARMACEUTICALS INCdex32.htm
EX-3.4 - FORM OF AMENDED AND RESTATED BYLAWS OF THE REGISTRANT - ACELRX PHARMACEUTICALS INCdex34.htm
EX-10.5 - FORMS OF STOCK OPTION GRANT NOTICE, STOCK OPTION EXCERCISE NOTICE AND.... - ACELRX PHARMACEUTICALS INCdex105.htm
EX-10.6 - FORM OF RESTRICTED STOCK UNIT AWARD AGREEMENT - ACELRX PHARMACEUTICALS INCdex106.htm
EX-10.4 - 2011 EQUITY INCENTIVE PLAN - ACELRX PHARMACEUTICALS INCdex104.htm
EX-10.1 - FORM OF INDEMNIFICATION AGREEMENT - ACELRX PHARMACEUTICALS INCdex101.htm
EX-10.7 - 2011 EMPLOYEE STOCK PURCHASE PLAN - ACELRX PHARMACEUTICALS INCdex107.htm
EX-10.17 - AMENDED AND RESTATED OFFER LETTER - RICHARD KING - ACELRX PHARMACEUTICALS INCdex1017.htm
EX-10.15 - AMENDED AND RESTATED OFFER LETTER - BADRI (ANIL) DASU - ACELRX PHARMACEUTICALS INCdex1015.htm
EX-10.13 - OFFER LETTER - THOMAS SCHRECK - ACELRX PHARMACEUTICALS INCdex1013.htm
EX-10.12 - FOUNDER'S VESTING AGREEMENT - THOMAS SCHRECK - ACELRX PHARMACEUTICALS INCdex1012.htm
EX-10.16 - AMENDED AND RESTATED OFFER LETTER - PAMELA PALMER - ACELRX PHARMACEUTICALS INCdex1016.htm
EX-10.14 - AMENDED AND RESTATED OFFER LETTER - LARRY HAMEL - ACELRX PHARMACEUTICALS INCdex1014.htm
EX-10.11 - FOUNDER'S VESTING AGREEMENT - PAMELA PALMER - ACELRX PHARMACEUTICALS INCdex1011.htm
EX-10.19 - RESIGNATION AGREEMENT - THOMAS SCHRECK - ACELRX PHARMACEUTICALS INCdex1019.htm
EX-10.18 - AMENDED AND RESTATED OFFER LETTER - JAMES WELCH - ACELRX PHARMACEUTICALS INCdex1018.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Experts” and to the use of our report dated June 30, 2010, in the Registration Statement (Amendment No. 2 to Form S-1) and related Prospectus of AcelRx Pharmaceuticals, Inc. for the registration of shares of its common stock.

/s/ Ernst & Young LLP

San Francisco, California

January 7, 2011

ACELRX PHARMACEUTICALS INC Reports